With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...
This project aims to bring cutting-edge molecular diagnostics to Saudi Arabia using a 23-gene panel to detect key genetic ...
Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, ...
Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...
1d
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to ...
GlobalData on MSN4d
KFSHRC partners with University of Birmingham for bladder cancer diagnosisKing Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia has entered a five-year partnership with the ...
A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...
This partnership unites the expertise of KFSHRC’s Urology Department with BCRC’s research capabilities to advance ...
Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...
Verywell Health on MSN3d
What to Expect From a Bladder UltrasoundA bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...
Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...
In a phase 1b trial, treatment of patients with muscle-invasive bladder cancer with intravesical oncolytic virus cretostimogene grenadenorepvec in combination with nivolumab was safe and led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback